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Abstract
Background: Several compounds isolated from Dryobalanops have been reported to exhibit cytotoxic effects to
several cancer cell lines. This study investigated the cytotoxic effects, cell cycle arrest and mode of cell death in
ampelopsin E-treated triple negative cells, MDA-MB-231.
Methods: Cytotoxicity of ampelopsin E, ampelopsin F, flexuosol A, laevifonol, Malaysianol A, Malaysianol D and
nepalensinol E isolated from Dryobalanops towards human colon cancer HT-29, breast cancer MDA-MB-231 and MCF-7,
alveolar carcinoma HeLa and mouse embryonic fibroblast NIH/3 T3 cells were determined by MTT assay. The cells were
treated with the compounds (0.94–30 μM) for 72 h. The mode of cell death was evaluated by using an inverted light
microscope and annexin V/PI analysis. Cell cycle analysis was performed by using a flow cytometer.
Results: Data showed that ampelopsin E was most cytotoxic toward MDA-MB-231 with the IC50 (50 % inhibition of cell
viability compared to control) of 14.5 ± 0.71 μM at 72 h. Cell shrinkage, membrane blebbing and formation apoptotic
bodies characteristic of apoptosis were observed following treatment with ampelopsin E. The annexin V/PI flow
cytometric analysis further confirmed that ampelopsin E induced apoptosis in MDA-MB-231 cells. Cell cycle analysis
revealed that ampelopsin E induced G2/M phase cell cycle arrest in the cells.
Conclusion: Ampelopsin E induced apoptosis and cell cycle arrest in MDA-MB-231 cells. Therefore, ampelopsin E has
the potential to be developed into an anticancer agent for treatment of triple negative breast cancer.
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Background
Cancer is a leading cause of mortality and morbidity
worldwide over the years. Approximately, 14.1 million
cancer cases and 8.2 million cancer-related deaths world-
wide were recorded in 2012. Breast cancer ranked as
second most commonly diagnosed cancer (1.67 million
cases) after lung cancer (1.82 million cases) [6]. Breast
cancer represents a heterogeneous group of tumors with
several characterizations based on their morphological
and biological features, behavior and response to treat-
ments [9]. It can be classified into different subgroups by
the expression of estrogen receptor (ER), progesterone re-
ceptor (PR) and human epidermal growth factor receptor
2 (HER2). Among all the breast cancers cases, 25 to 30 %
of them are ER negative or triple negative breast cancer
(TNBC) known to be most aggressive with high metastatic
potential [17] especially to the vital organs such as brain
and lungs. Approximately, over 80 % of hereditary BRCA1
mutation is TNBC [21]. Chemotherapy is the common
treatment for TNBC patients (the use of taxanes, ixabepi-
lones, anthracyclines, platinum agents, biologic agents and
anti-EGFR drugs) [13]. However, the treatment comes
with adverse effects including multidrug resistance and
congestive heart failure [2]. Therefore, new drug for man-
agement of TNBC is in great demand.
Natural products play an important role in cancer
research. There are about more than two third of the cur-
rently available anticancer agents are derived from natural
products between 1940s to 2006 [29]. The Dryobalanops
or locally called as Kapur from Dipterocarpaceae family
can only be found in the tropical forest of Malesia such as
Peninsular Malaysia, Sumatra and Borneo [3]. It is very
unique with only seven species worldwide including D.
rappa, D. aromatica, D. lanceolata, D. beccarii, D. fusca,
D. keithii and D. oblongifolia. Approximately 200
oligostilbenoid constituents have been isolated from
Dipterocarpacea family [15]. The uniqueness and com-
plexity of the structure of oligostilbenoid in each genera
has attracted scientists from various fields to investigate
its phytochemical constituents, bioactivities, biogenesis
and chemotaxonomy [34]. There are several types of oli-
gostilbenoid constituents including ampelopsin E [27],
flexuosol A [22] and Malaysianol D [34] found in D.
beccarii. Malaysianol A was successfully isolated from D.
aromatica [33], while nepalensinol E [35], ampelopsin
F [31] and laevifonol [11] can be found mostly in all
Dryobalanops sp. Oligostilbenoid constituents were
reported to possess some bioactivities such as anti-
diabetogenic effect [24] and anti-angiogenesis [18]. In the
previous study, Wibowo et al. [34] reported that ampelop-
sin E was the most cytotoxic towards breast adenocarcin-
oma cells (MCF-7). However, there is no yet any study on
the mechanisms underlying the cytotoxicity of oligostilbe-
noid compounds especially ampelopsin E towards cancer
cell lines. This study investigated the cytotoxic effects, cell
cycle arrest and mode of cell death involved in ampelopsin
E-treated triple negative cells, MDA-MB-231.
Methods
Compounds
Pure compounds of Dryobalanops (Dryobalanops aroma-
tica Gaertn, Dryobalanops beccarii Dyer and Dryobalanops
lanceolata Burck and Dryobalanops rappa Becc) which
are ampelopsin E, ampelopsin F, flexuosol A, laevifonol,
Malaysianol A, Malaysianol D and nepalensinol E, were
kindly supplied by the Faculty of Applied Sciences,
Universiti Teknologi MARA, Shah Alam, Selangor,
Malaysia.
Reagents and chemicals
RPMI-1640 without phenol red (Roswell Park Memorial
Institute Medium) was purchased from Nacalai Tesque
Inc (Kyoto, Japan). DMEM-F12 (Dulbeco’s Modified
Eagle Medium), epidermal growth factor (EGF), hydro-
cortisone, cholera toxin, insulin, trypan blue solution,
MTT powder, propidium iodide (PI) and RNase A were
purchased from Sigma-Aldrich, St. Louis, MO, USA.
Penicillin-streptomycin antibiotic and trypsin-EDTA
were purchased from PAA Laboratories (Pasching,
Austria). MycoplexTM foetal bovine serum (FBS) was
purchased from Commerce Ave (California, USA).
Cell culture
The dependent-hormonal breast adenocarcinoma (MCF-7),
independent-hormonal breast adenocarcinoma (MDA-
MB-231), human colon adenocarcinoma (HT29), alveolar
carcinoma (A-549), cervical adenocarcinoma (HeLa),
mouse embryonic fibroblast (NIH/3 T3) and normal breast
epithelial (MCF-10A) cell lines were purchased from the
American Type and Culture Collection (ATCC), USA. All
the cell lines except MCF-10A were cultured in RPMI-
1640 medium supplemented with 10 % foetal bovine serum
(FBS) and 1 % antibiotics (100 IU/mL penicillin and
100 μg/mL streptomycin) and maintained in a 37 °C incu-
bator with humidified atmosphere of 5 % CO2. MCF-10A
cells were cultured in DMEM-F12 medium supplemented
with 10 % foetal bovine serum, 0.5 mg/mL hydrocortisone,
10 μg/mL insulin, 100 ng/mL cholera toxin and 20 ng/mL
epidermal growth factor.
Determination of cytotoxicity
The cytotoxic effects of the compounds were evaluated by
the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide] assay [25]. The cells (50,000 cells/mL)
were treated with various concentrations of the com-
pounds (0.94–30 μM) in a 96-well plate for 72 h. Un-
treated controls were also included. Following incubation,
20 μL of 5 mg/mL MTT solution was added to each well
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and incubated at 37 °C for 3 h. Next, 100 μL of DMSO
was added to dissolve the purple precipitate of formazan
crystal. The absorbance at 570 nm and 630 nm as refer-
ence wavelength was measured by a microplate reader
(BioTek EL 800, United States). The IC50 (concentration
of the compound that will cause 50 % inhibition of cell
growth compared to the control [1]) was obtained from
the fit standard curve of percentage cell viability on the
ordinate against the compound concentration on the
abscissa:
Cell growth inhibition (%) = [1 - (ODTreated/OD
Control)] × 100.
Based on the IC50 value, the most potent compound
was subjected to further analysis.
Determination of morphological changes
Briefly, 150,000 cells per well of MDA-MB-231 cells were
seeded in a 6-well plate and incubated for 24 h. Next, the
cells were treated with ampelopsin E (7.5–30 μM) and
further incubated for 72 h. The untreated cells were in-
cluded as a control. The image was captured at 0, 24, 48
and 72 h at the same spot under an inverted microscope
(Olympus, Japan).
Determination of cell cycle arrest
MDA-MB-231 cells were seeded at 800,000 cells per
75 cm2 flask. Next, the cells were treated with ampelop-
sin E (7.5–30 μM). The untreated cells were also in-
cluded as a control. The cells were incubated for 24, 48
and 72 h. Next, the cells were trypsinized, washed twice
with ice cold PBS and collected. The cell pellet was fixed
with ice-cold 70 % ethanol and stored at −20 °C. After a
week, the cells were washed once again with ice-cold PBS.
The cell pellet was mixed up with 250 μL Guava cell cycle
reagents (EMD, Milliport Corporation, Hayward) and
300 μL PBS. The population of cells in each phase was
measured by a flow cytometer (FACSCalibur, Becton
Dickinson, USA). The results were analysed by using
ModFit LT™ software.
Determination of mode of cell death
Human Annexin V/PI Apoptosis Detection Kit I (BD
Biosciences Pharmingen, Franklin Lakes, NJ, USA) was
used to determine the mode of cell death induced by
ampelopsin E. Briefly, the MDA-MB-231 cells were
seeded at 150,000 cells per well in a 6-well plate. Next,
the cells were treated with ampelopsin E (7.5–30 μM).
The untreated cells were also included as a control. The
cells were harvested and washed with 2 mL of ice-cold
PBS. Subsequently, the samples were mixed with 100 μL
of 4X binding buffer on ice. Next, in the dark, 5 μL
annexin V and 5 μL of propidium iodide (1 mg/mL)
were added with 15 min of incubation on ice. Next,
400 μL of 4X binding buffer was added to dilute the
samples. The cells were analyzed by using FACS Calibur
flow cytometer (Becton Dickinson, USA). The results
were analysed by using FlowJo version 8.6 (Treestar Inc.,
San Carlos, CA).
Statistical analysis
All values were expressed as mean ± standard deviation
(SD). The data were analyzed by one-way analysis of
variance (ANOVA) followed by Dunnet using Statistical
Package for Social Science (SPSS) version 21.0. Probability
of p < 0.05 was considered statistically significant.
Results
Ampelopsin E was cytotoxic and inhibited growth of
MDA-MB-231 cells
From Table 1, ampelopsin E, Malaysianol A and flexuo-
sol A were cytotoxic towards MDA-MB-231 cells at
14.5, 23 and 27.5 μM, while ampelopsin E was cytotoxic
towards MCF-7 cells at 29.5 μM in a time- and
concentration-dependent. Tamoxifen and doxorubicin
were cytotoxic towards both MDA-MB-231 at 7 and
0.4 μM, respectively, and MCF-7 at 11.5 and 0.21 μM,
respectively. Treatment with ampelopsin E at 15–30 μM
resulted in significant reduction (p < 0.05) in the cell
viability.
The IC50 values of ampelopsin E towards MDA-MB-
231 cells at 24, 48 and 72 h were 30 ± 0.13, 16 ± 2.01 and
14.5 ± 0.71 μM, respectively (Fig. 1a). The IC50 value
of ampelopsin E towards MCF-7 cells at 72 h was
29.5 ± 0.71 μM (Table 1B). Ampelopsin E was less cyto-
toxic towards MCF-10A normal breast epithelial cells with
IC50 more than 30 μM (Fig. 1c). The IC50 of doxorubicin
(positive control) towards MDA-MB-231 cells at 72 h was
0.4 ± 0 μM (Fig. 1d). Based on the cytotoxic effect, 7.5, 15
and 30 μM of ampelopsin E, and incubation time of 24
and 48 h were selected for further analysis.
The morphological changes of MDA-MB-231 cells treated
with ampelopsin E
From Fig. 2a, the number of MDA-MB-231 cells re-
duced at 15 and 30 μM of ampelopsin E at 48 to 72 h.
Cell detachment, cell shrinkage and formation apoptotic
bodies were observed at 48 and 72 h in MDA-MB-231
cells treated with 30 μM of ampelopsin E (Fig. 2b). At
7.5 μM of ampelopsin E, membrane blebbing was noted
while at 15 μM of the compound, cell shrinkage was
observed. Nevertheless, the cell number increased
over time.
Ampelopsin E induced G2/M arrest in MDA-MB-231 cells
The cell cycle arrest of MDA-MB-231 cells by ampe-
lopsin E was time- and concentration-dependents
(Fig. 3). At 24, 48 and 72 h, an increase in G2/M
population at 15 and 30 μM of ampelopsin E was
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noted (p < 0.05). In addition, at 7.5, 15 and 30 μM of
ampelopsin E at 72 h, increase in the number of cells
in S phase compared to control, accompanied by a
decline in G0/G1 phase cell population was observed
(p < 0.05).
Ampelopsin E induced apoptosis in MDA-MB-231 cells
Ampelopsin E induced apoptosis in MDA-MB-231 cells.
At 24 h, the percentage of viable cells decreased from
75.3 % at 7.5 μM, 69.0 % at 15 μM and 57.1 % at 30 μM
of ampelopsin E compared to 89.9 % in the control
Table 1 Cytotoxicity of oligostilbenoid compounds isolated from Dryobalanops towards cancer cell lines and non-tumorigenic cell


















MDA-MB-231 27.5 ± 3.54 >30 >30 >30 14.5 ± 0.71 23 ± 4.24 >30 7 ± 1.41 0.4 ± 0
MCF-7 >30 >30 >30 >30 29.5 ± 0.71 >30 >30 11.5 ± 3.54 0.21 ± 0.27
HT-29 >30 >30 >30 >30 >30 N/A N/A N/A N/A
A-549 >30 >30 >30 >30 >30 N/A N/A N/A N/A
HeLa >30 >30 >30 >30 >30 N/A N/A N/A N/A
3T3 >30 >30 >30 >30 >30 N/A N/A N/A N/A
MCF10A >30 N/A N/A N/A >30 >30 >30 N/A >10





























































































Fig. 1 Effects of ampelopsin E on the viability of a MDA-MB-231, b MCF-7 and c MCF10A as determined by MTT assay. Antiproliferative effect of
ampelopsin E was high compared to reference drug, doxorubibin on MDA-MB-231 cell line (d). The data are represented as mean percentage of
viable cells ± SD of two replicates in two independent tests
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(p < 0.05). From Fig. 4, the percentage of early apoptotic
cells increased in a time- and concentration-dependent
manner. At 72 h, the percentage of early apoptotic in-
creased from 12.9 % at 7.5 μM, 23.6 % at 15 μM and
33.9 % at 30 μM of ampelopsin E compared to 5.49 % in
the control (p < 0.05).
Discussion
Previously, from a study done by Fisher et al. [7], the use
of tamoxifen should continue to treat breast cancer be-
cause of net benefit greatly outweighs the risk (increase
severity of cancer). However, plants also are a good and
potential source of anticancer agents especially to re-
place the drug such as tamoxifen with some adverse
effects. For instance, vindesine from Catharanthus roseus
[5], taxol from Taxus brevifolia [20], beta-lapachone from
Tabebuia avellanedae [23] and genistein from Glycin max
[19] have been employed clinically to treat breast cancer
patients.
In this study, several compounds isolated from
Dryobalanops sp (ampelopsin E, ampelopsin F, flexuosol
A, laevifonol, Malaysianol A, Malaysianol D and nepa-
lensinol E) were tested towards various cell lines (MDA-
MB-231, MCF-7, HT-29, A-549, HeLa, 3 T3 and
MCF10A). Based on the IC50 values, ampelopsin E was
the most cytotoxic towards MDA-MB-231 cells at
14.5 μM compared to MCF-7, HT-29, A-549, HeLa,
3 T3 and MCF10A. Ampelopsin E, Malaysianol A and
Malaysianol D are stereoisomer with similar basic skel-
eton [34]. Based on Wibowo et al. [34], Malaysianol A
and ampelopsin E exhibited almost similar cytotoxic ef-
fects, but Malaysianol D showed lower activity towards
MCF-7 and A-549. The free stilbene skeleton of flexuo-
sol A has no contribution at all. It is suggested that the
polarity and stereochemistry of oligostilbenoid constitu-
ents are important factors influencing their cytotoxicity.
According to the National Cancer Institute (NCI) guide-
lines, ampelopsin E can be considered as a great candi-
date to be developed as an anticancer agent for breast
cancer as the IC50 value was less than 15 μM towards
MDA-MB-231 cells after treatment for 72 h. Ampelop-
sin E was most potent towards the triple negative hor-
mone receptor breast cancer cell line, MDA-MB-231.
Some proteins may be related to the mechanism of drug
resistance in MDA-MB-231 cells especially in DNA re-
combination, cell cycle, complex assembly, cytoskeleton
organization, transport and negative regulation of cell
death [30]. Therefore, it is deduced that ampelopsin E is
a good candidate for treating drug resistant breast can-
cer. Ampelopsin E was cytotoxic towards the cells in a












Fig. 2 a Morphological changes of ampelopsin E-treated MDA-MB-231 cells observed under an inverted light microscope (100 × magnification).
Cell population decreased with the increase in the compound concentration. b The ampelopsin E-treated MDA-MB-231 cells showed the features
of apoptosis such as membrane blebbing (MB), cellular shrinkage (CS) and formation of apoptotic bodies (AB) at 48 to 72 h (400× magnification)
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time- and concentration-dependent manner. Ampelop-
sin E was less cytotoxic towards normal cells (3 T3 and
MCF10A) compared to the cancer cells. This suggests
selectivity of ampelopsin E towards cancer cells.
Wibowo et al. [34] reported that ampelopsin E from
Dryobalanops beccarii was most cytotoxic towards
MCF-7 (IC50 = 20.98 μM). Nevertheless, in this study,
ampelopsin E was the most cytotoxic towards MDA-
MB-231 (IC50 = 14.5 μM). The IC50 towards MCF-7 was
29.5 μM. The difference is believed due to batch-to-
batch variation of the cells.
The ability of ampelopsin E to induce apoptosis in
MDA-MB-231 suggests that it has the potential as a new
candidate of anticancer agent against independent-
hormonal breast cancer. Plant extracts or compounds
such as phenolics, flavonoids, tea polyphenols, alkaloids,
polysaccharides and glycoproteins, lectins, tannins and
lignins, terpenoids, isoprenoids and quinones [32] have
been reported to selectively induce apoptosis in neoplas-
tic cells instead of normal cells.
Ampelopsin E inhibited the growth of MDA-MB-231
cells in a time- and concentration- dependent manner.
Several features of apoptosis were noted at 48 and 72 h
such as membrane blebbing, cellular shrinkage and
formation of apoptotic bodies [26]. There are several
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Fig. 3 Cell cycle profile of MDA-MB-231 cells treated with ampelopsin E (a and b). Each data point represents the mean of three independent
experiments ± SD. *significantly different from the control (p < 0.05)
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on their biochemical and morphological characteristics,
which are apoptosis, autophagy, necrosis, mitotic catas-
trophe and senescence (in cancer therapy context).
Treatments that can increase the rate of apoptosis could
be used to manage cancers [10] because apoptosis is a
self-destructive mode that involves only the individual
cells and will not cause inflammation especially to the
neighboring cells [16].
Inhibition of cell growth at 15 and 30 μM of ampelop-
sin E between 48 and 72 h was due to cell cycle arrest at
G2/M phase as being confirmed by flow cytometer ana-
lysis evidenced by a significant increased population in
G2/M phase with decrease cell number of S phase. The
major regulator of G2 to M transition is the M-phase-
promoting factor (MPF) such as catalytic subunit cdc2
and regulatory subunit cyclin B1 [37]. From the study
done by Huang et al. [12], dihydromyricetin isolated
from Ampelopsis grossedentata induced G2/M phase cell
cycle arrest through Chk1/Chk2/Cdc25C pathway. The
important key roles in this pathway are the formation of
CDK1/cyclin B1 and CDK1/cyclin A complexes.
Evasion of apoptosis is the requirement for cancer cells
to survive [14]. Thus, understanding the apoptosis signal-
ing pathways and the mechanism of resistance towards
apoptosis are vital to manage cancer [14]. Apoptosis is a
programmed cell death, which is important in animal de-
velopment, tissue homeostasis and other disease process
[36] as the common response to cell stress induced by
physiological changes, drugs, agents or toxins [10]. There
are two types of apoptotic pathway, which are extrinsic
and intrinsic pathway. In the extrinsic pathway, the com-
monly involved proteins are TNF-alpha and NF-kappaB.
TNF-α will give response towards any environmental
changes such as injury and inflammation that result in
apoptosis [4]. TNF-α activation can promote NF-ƙB to
participate in development, survival, proliferation and me-
tastases in cancer [28]. In the intrinsic pathway, apoptosis
involves mitochondria dysfunction of Bcl-2 family of
A)
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Fig. 4 The percentage of viable, apoptotic and necrotic/secondary necrotic cells of untreated andampelopsin E-treated MDA-MB-231 cells for 24
and 48 h as determined by flow cytometer. a and b These are from representative experiments carried out at least three times. The percentage
of viable cells were represented by lower left quadrant (Annexin-V−/PI−); the percentage of early apoptotic and necrotic/secondary necrotic cells
were represented by the lower right (Annexin-V+/PI−) and upper (PI+) quadrants, respectively. Each data point represents the mean of three
independent experiments ± SD. *significantly different from the control (p < 0.05)
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proteins. Bcl-2 family includes pro-apoptotic (Bax, Bak,
Bad and Bim) and anti-apoptotic (Bcl-2, Bcl-xL and
Mcl-1) [36].
The induction of apoptosis by ampelopsin E in MDA-
MB-231 cells was confirmed by annexin V/propidium iod-
ide (annV/PI). Generally in in vivo, the apoptotic bodies
are engulfed by phagocytocytes such as neutrophils and
macrophages. However, in vitro system lack of these
phagocytes, the apoptotic bodies membrane will rupture
and accessible to PI dye. Therefore, the secondary necrotic
cells are stained by annexin V and PI [8]. From the princi-
ples, apoptotic and necrotic cells can be differentiated.
Conclusion
In conclusion, ampelopsin E was most cytotoxic towards
MDA-MB-231 cells. Ampelopsin E caused G2/M phase
cell cycle arrest and induced apoptosis in the cells. Thus,
ampelopsin E has potential to be developed as an anti-
breast cancer agent, especially for the independent-
hormonal breast cancer.
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